Guggenheim Capital LLC Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)

Guggenheim Capital LLC bought a new stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 19,759 shares of the biotechnology company's stock, valued at approximately $782,000.

Other institutional investors have also made changes to their positions in the company. Jones Financial Companies Lllp lifted its position in shares of Veracyte by 49.7% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock worth $28,000 after buying an additional 237 shares during the last quarter. US Bancorp DE increased its holdings in Veracyte by 57.4% during the fourth quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock worth $70,000 after buying an additional 647 shares during the last quarter. Principal Securities Inc. boosted its holdings in Veracyte by 34.1% in the 4th quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock worth $76,000 after buying an additional 485 shares during the period. Venturi Wealth Management LLC purchased a new stake in Veracyte in the 4th quarter worth approximately $91,000. Finally, Sterling Capital Management LLC boosted its holdings in shares of Veracyte by 810.2% in the 4th quarter. Sterling Capital Management LLC now owns 2,421 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 2,155 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts recently issued reports on VCYT shares. Stephens reiterated an "overweight" rating and set a $45.00 price target on shares of Veracyte in a research report on Wednesday, March 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $51.00 price objective on shares of Veracyte in a research note on Tuesday, February 25th. Guggenheim decreased their price target on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Craig Hallum started coverage on Veracyte in a report on Thursday, March 20th. They set a "buy" rating and a $45.00 price objective for the company. Finally, StockNews.com cut Veracyte from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Veracyte presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.60.

Veracyte Trading Down 1.4 %

VCYT stock traded down $0.43 on Tuesday, hitting $31.24. The company's stock had a trading volume of 105,271 shares, compared to its average volume of 859,771. Veracyte, Inc. has a 1 year low of $19.48 and a 1 year high of $47.32. The firm has a 50 day moving average of $32.04 and a two-hundred day moving average of $37.34. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -208.49 and a beta of 2.03.

Veracyte (NASDAQ:VCYT - Get Free Report) last announced its earnings results on Monday, February 24th. The biotechnology company reported $0.36 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.07. The firm had revenue of $118.63 million for the quarter, compared to analysts' expectations of $110.73 million. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. During the same quarter in the prior year, the firm earned ($0.39) EPS. As a group, equities analysts forecast that Veracyte, Inc. will post 0.68 EPS for the current fiscal year.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.